RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $215 from $139 and keeps an Outperform rating on the shares after its Q3 results. The firm is impressed by Brinsupri’s early commercial performance in bronchiectasis that handily beat expectations, and based on key opinion leader feedback and early signs, RBC remains confident that the trajectory is sustainable, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $223 from $194 at UBS
- Strong Buy Rating for Insmed Driven by Brinsupri’s Success and Promising Pipeline
- Insmed price target raised to $217 from $171 at Wells Fargo
- Insmed’s Q3 2025 Earnings Highlight Growth and Expansion
- Strong Financial Performance and Promising Pipeline Drive Buy Rating for Insmed